Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Operating Income: 2019-2024

Historic Operating Income for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to -$358.8 million.

  • Lyell Immunopharma's Operating Income rose 26.24% to -$37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$342.9 million, marking a year-over-year decrease of 57.94%. This contributed to the annual value of -$358.8 million for FY2024, which is 45.24% down from last year.
  • According to the latest figures from FY2024, Lyell Immunopharma's Operating Income is -$358.8 million, which was down 45.24% from -$247.0 million recorded in FY2023.
  • Lyell Immunopharma's Operating Income's 5-year high stood at -$187.1 million during FY2022, with a 5-year trough of -$358.8 million in FY2024.
  • For the 3-year period, Lyell Immunopharma's Operating Income averaged around -$264.3 million, with its median value being -$247.0 million (2023).
  • Its Operating Income has fluctuated over the past 5 years, first slumped by 107.60% in 2020, then grew by 12.91% in 2022.
  • Lyell Immunopharma's Operating Income (Yearly) stood at -$211.9 million in 2020, then fell by 1.34% to -$214.8 million in 2021, then increased by 12.91% to -$187.1 million in 2022, then tumbled by 32.05% to -$247.0 million in 2023, then slumped by 45.24% to -$358.8 million in 2024.